Administration of anti-PD-1 and/or anti-PD-L1 monoclonal antibodies (MAbs) unblocks immune inhibition via PD-1/PD-L1 bridging and enhances tumor cell killing by the CD8 + CTLs [28]. Here, CD8A is linked to neoplasm.